51岁牛散郭伟松出手，举牌上市药企华特达因

Core Points - Guo Weisong increased his stake in Huate Dain by purchasing 24,400 shares, bringing his total holdings to 11.7166 million shares, which represents 5% of the company [1] - As of today, Huate Dain's total market capitalization is 6.751 billion yuan, valuing Guo's shares at approximately 338 million yuan [1] - Guo Weisong has been actively buying shares over the past six months, accumulating a total of 979,300 shares for an investment of 30.14 million yuan [2] - Guo stated that his investment decision is based on an analysis of Huate Dain's value and future prospects, aiming to establish a long-term investment relationship rather than seeking control [2] - Guo Weisong's shareholding in Huate Dain has fluctuated, starting at 3.96% in Q1 2024, increasing to 4.95% by mid-2024, and then decreasing to 4.57% after selling 890,000 shares [2] - The stock price of Huate Dain has experienced significant volatility, with a price fluctuation of 57.97% and a maximum drawdown of over 33% since January 2024, resulting in a cumulative increase of 17.78% [3] - Huate Dain's main products include children's medicines and health nutrition products, with a focus on the children's health industry [3] - The primary revenue and profit source for Huate Dain comes from its subsidiary, Dain Pharmaceutical, which has a leading market share in children's medicines [3] - The product "Yikexin" has over 60% market share in its category, used for preventing and treating vitamin A and D deficiencies [3] - Guo Weisong has participated in multiple private placements of listed companies, including Nanshan Zhishang, where he acquired shares worth 99.4 million yuan [4]